Novartis Restructure Sees Drug Development And Oncology Chiefs Exit
Aims To Boost R&D And Commercial Performance
Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.
You may also be interested in...
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.
Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.